Cabaletta Bio (NASDAQ:CABA) 주식

Cabaletta Bio

Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) has the potential to be applied across a broad range of autoimmune diseases.

Equities

Markets

CABA

카발레타 바이오(NASDAQ:CABA)의 주가는 수요일 24.38% 상승한 3.01달러에 마감했으며, 전신 경화증(Systemic Sclerosis) 약물 시험 업데이트 이후 시간외 거래에서 4.65% 상승한 주당 3.15달러에 거래되었다.

카발레타 바이오, 전신 경화증 약물 시험 업데이트 이후 수요일 23개월 만에 최대 급등

Cabaletta Bio Inc

Cabana Target Beta ETF

Cabana Target Drawdown 10 ETF

Cabana Target Leading Sector Moderate ETF

News

Buybacks

ELMD

Electromed Announces Its Board of Directors Authorizes The Repurchase Of Up To $5M Of Electromed Common Stock.

Oppenheimer analyst Scott Schneeberger maintains WillScot Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WSC#NASDAQ">WSC</a>) with a Outperform and lowers the price target from $41 to $38.

Price Target

Analyst Ratings

Oppenheimer Maintains Outperform on WillScot Holdings, Lowers Price Target to $38

Analysts' ratings for SLM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLM#NASDAQ">SLM</a>) over the last quarter vary from bullish to bearish, as provided by 9 analysts.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $33.11, a high estimate of $38.00, and a low estimate of $29.00. Marking an increase of 9.96%, the current average surpasses the previous average price target of $30.11. 
<img src="https://www.benzinga.com/files/images/story/2025/1741611638_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The standing of SLM among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jeffery Harte</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$38.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Mark Devries</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$38.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Jon Afstrom</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$32.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Richard Shane</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$30.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Michael Kaye</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$33.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Giuliano Bologna</td>
<td>Compass Point</td>
<td>Raises</td>
<td>Buy</td>
<td>$34.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Sanjay Sakhrani</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$32.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Richard Shane</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$29.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Jeffery Harte</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$32.00</td>
<td>$26.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to SLM. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of SLM compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of SLM's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of SLM's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/SLM/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on SLM analyst ratings.</a>
<h2>Unveiling the Story Behind SLM</h2>
SLM Corp is an education solutions company. It business is to originate and service loans to students and their families to finance the cost of their education. The provide Private Education Loans to mean education loans to students or their families that are not made, insured, or guaranteed by any state or federal government.
<h3>SLM's Economic Impact: An Analysis</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: SLM's revenue growth over a period of 3 months has faced challenges. As of 31 December, 2024, the company experienced a revenue decline of approximately -11.97%. This indicates a decrease in the company's top-line earnings. When compared to others in the Financials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: SLM's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 27.49%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): SLM's ROE stands out, surpassing industry averages. With an impressive ROE of 5.65%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): SLM's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 0.36%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: SLM's debt-to-equity ratio surpasses industry norms, standing at 3.37. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>Analyst Ratings: What Are They?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Down SLM: 9 Analysts Share Their Views

14 analysts have shared their evaluations of Progressive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PGR#NYSE">PGR</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">10</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Progressive and provided 12-month price targets. The average target is $294.93, accompanied by a high estimate of $318.00 and a low estimate of $256.00. Witnessing a positive shift, the current average has risen by 0.53% from the previous average price target of $293.38.
<img src="https://www.benzinga.com/files/images/story/2025/1741611628_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
A clear picture of Progressive's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joshua Shanker</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$318.00</td>
<td>$333.00</td>
</tr>
<tr>
<td>Harry Fong</td>
<td>Roth MKM</td>
<td>Raises</td>
<td>Buy</td>
<td>$315.00</td>
<td>$290.00</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$317.00</td>
<td>$313.00</td>
</tr>
<tr>
<td>Alex Scott</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$264.00</td>
<td>$261.00</td>
</tr>
<tr>
<td>Bob Huang</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$307.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$313.00</td>
<td>$302.00</td>
</tr>
<tr>
<td>Bob Huang</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$300.00</td>
<td>$310.00</td>
</tr>
<tr>
<td>Meyer Shields</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$294.00</td>
<td>$295.00</td>
</tr>
<tr>
<td>Alex Scott</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$261.00</td>
<td>$277.00</td>
</tr>
<tr>
<td>Jimmy Bhullar</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$256.00</td>
<td>$251.00</td>
</tr>
<tr>
<td>C. Gregory Peters</td>
<td>Raymond James</td>
<td>Announces</td>
<td>Outperform</td>
<td>$305.00</td>
<td>-</td>
</tr>
<tr>
<td>Michael Zaremski</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$267.00</td>
<td>$273.00</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$302.00</td>
<td>$299.00</td>
</tr>
<tr>
<td>Bob Huang</td>
<td>Morgan Stanley</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$310.00</td>
<td>$310.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Progressive. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Progressive compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Progressive's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/PGR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Progressive analyst ratings.</a>
<h2>Delving into Progressive's Background</h2>
Progressive underwrites private and commercial auto insurance and specialty lines; it has almost 20 million personal auto policies in force and is one of the largest auto insurers in the United States. Progressive markets its policies through independent insurance agencies in the US and Canada and directly via the internet and telephone. Its premiums are split roughly equally between the agent and the direct channel. The company also offers commercial auto policies and entered homeowners insurance through an acquisition in 2015.
<h3>Breaking Down Progressive's Financial Performance</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Growth: Progressive's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 20.04%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Financials sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Progressive's net margin excels beyond industry benchmarks, reaching 11.63%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Progressive's ROE stands out, surpassing industry averages. With an impressive ROE of 8.93%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Progressive's ROA stands out, surpassing industry averages. With an impressive ROA of 2.23%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Progressive's debt-to-equity ratio is below the industry average at 0.27, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: What Are They?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Forecasting The Future: 14 Analyst Projections For Progressive

Barclays analyst Saket Kalia initiates coverage on SailPoint (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIL#NASDAQ">SAIL</a>) with a Overweight rating and announces Price Target of $27.

Initiation

SAIL

Barclays Initiates Coverage On SailPoint with Overweight Rating, Announces Price Target of $27

Mizuho analyst Gregg Moskowitz initiates coverage on SailPoint (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIL#NASDAQ">SAIL</a>) with a Neutral rating and announces Price Target of $25.

Mizuho Initiates Coverage On SailPoint with Neutral Rating, Announces Price Target of $25

Earnings

Earnings Beats

PPBT

Purple Biotech Q4 EPADS $(0.26)

Mizuho analyst Vijay Rakesh initiates coverage on SanDisk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDK#NASDAQ">SNDK</a>) with a Outperform rating and announces Price Target of $60.

SNDK

Mizuho Initiates Coverage On SanDisk with Outperform Rating, Announces Price Target of $60

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Jefferies analyst Linda Tsai initiated coverage on SailPoint, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIL#NASDAQ">SAIL</a>) with a Buy rating and announced a price target of $26. SailPoint shares closed at $22.05 on Friday. <a href="https://www.benzinga.com/quote/SAIL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup analyst Jason Gursky initiated coverage on Karman Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KRMN#NYSE">KRMN</a>) with a Buy rating and announced a price target of $42. Karman shares closed at $28.78 on Friday. <a href="https://www.benzinga.com/quote/KRMN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>D. Boral Capital analyst Jason Kolbert initiated coverage on Pulmonx Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNG#NASDAQ">LUNG</a>) with a Buy rating and announced a price target of $17. Pulmonx shares closed at $7.48 on Friday. <a href="https://www.benzinga.com/quote/LUNG/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities analyst Tim Anderson initiated coverage on Aardvark Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AARD#NASDAQ">AARD</a>) with a Buy rating and announced a price target of $22. Aardvark Therapeutics shares closed at $10.13 on Friday. <a href="https://www.benzinga.com/quote/AARD/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley analyst Keith Weiss initiated coverage on SailPoint, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIL#NASDAQ">SAIL</a>) with an Equal-Weight rating and announced a price target of $26. SailPoint shares closed at $22.05 on Friday. <a href="https://www.benzinga.com/quote/SAIL/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying LUNG stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="562" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/10085530/image-50-1024x562.png" alt="" class="wp-image-816610" style="width:530px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/10085530/image-50-1024x562.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/10085530/image-50-300x165.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/10085530/image-50-768x421.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/10085530/image-50.png 1148w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/03/44187903/top-2-consumer-stocks-that-could-blast-off-this-quarter">Top 2 Consumer Stocks That Could Blast Off This Quarter</a></li>
</ul>

Pre-Market Outlook

Trading Ideas

AARD

KRMN

LUNG

This Pulmonx Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

ELAB

Morgan Stanley analyst Jeffery Harte maintains SLM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLM#NASDAQ">SLM</a>) with a Overweight and raises the price target from $32 to $38.

Morgan Stanley Maintains Overweight on SLM, Raises Price Target to $38

As of March 10, 2025, three stocks in the financial sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>&lt;/a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.  
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Jack Henry &amp; Associates Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JKHY#NASDAQ">JKHY</a>)</h3>
<ul>
<li>On Feb. 4, Jack Henry &amp; Associates posted in-line quarterly earnings. According to Greg Adelson, President and CEO, &#8220;We are pleased to report solid performance in the second quarter of our fiscal year. We continued our positive sales momentum with record sales attainment in Q2 for the second consecutive year while maintaining a robust sales pipeline for future opportunities.&#8221; The company's stock gained around 10% over the past five days and has a <a href="https://www.benzinga.com/quote/JKHY">52-week high of $193.02</a>.</li>
<li>RSI Value: 77.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>JKHY Price Action: Shares of Jack Henry &amp; Associates gained 4.2% to close at $191.28 on Friday.</li>
</ul>
<h3 class="wp-block-heading">Dynex Capital Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DX#NYSE">DX</a>)</h3>
<ul>
<li>On Feb. 20, Dynex Capital increased its monthly dividend from 15 cents to 17 cents. The company's stock gained around 8% over the past month and<a href="https://www.benzinga.com/quote/DX"> has a 52-week high </a>of $14.46.</li>
<li>RSI Value: 72.2</li>
<li>DX Price Action: Shares of Dynex Capital gained 2.5% to close at $14.37 on Friday.</li>
</ul>
<h3 class="wp-block-heading">Prudential PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PUK#NYSE">PUK</a>)</h3>
<ul>
<li>On June 24, 2024, Prudential launched a share buyback program worth $2 billion. The company expects to complete the share buyback no later than mid-2026. CEO Anil Wadhwani, said, "Progress towards our financial objectives will increase the potential for further cash returns to shareholders. Our dividend policy remains unchanged, with the Board continuing to expect the 2024 annual dividend to grow in the range of 7-9 per cent." The company's stock gained around 16% over the past month and has a <a href="https://www.benzinga.com/quote/PUK">52-week high </a>of $21.27.</li>
<li>RSI Value: 71</li>
<li>PUK Price Action: Shares of Prudential gained 2.2% to close at $19.64 on Friday.</li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/03/44187903/top-2-consumer-stocks-that-could-blast-off-this-quarter">Top 2 Consumer Stocks That Could Blast Off This Quarter</a></li>
</ul>

Short Ideas

JKHY

Top 3 Financial Stocks That May Fall Off A Cliff In March

Rosenblatt analyst Barton Crockett maintains Nexstar Media Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXST#NASDAQ">NXST</a>) with a Buy and maintains $200 price target.

NXST

Rosenblatt Maintains Buy on Nexstar Media Gr, Maintains $200 Price Target

Morgan Stanley analyst Kristine Liwag maintains Rocket Lab USA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) with a Equal-Weight and raises the price target from $18 to $20.

RKLB

Morgan Stanley Maintains Equal-Weight on Rocket Lab USA, Raises Price Target to $20

Franco-Nevada Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FNV#NYSE">FNV</a>) shares are trading higher premarket on Monday after the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/n44214573/franco-nevada-reports-q4-and-year-end-2024-results" rel="noreferrer noopener">company reported fourth-quarter results</a>.
Revenue rose 6% year over year (+30% Y/Y excluding Cobre Panama) to $321.0 million, beating the consensus of $305.85 million.
The company saw strong production from Candelaria, new assets, and benefiting from record gold prices. The company sold 120,063 GEOs in the quarter, down 21% Y/Y, owing to impact of the production halt at Cobre Panama.
As of December 31, 2024, Franco-Nevada held 6,216 stream gold ounces and 150,000 stream silver ounces in inventory.
Adjusted EBITDA increased 9% Y/Y to $277.4 million in the quarter. Adjusted EPS of&nbsp;$0.95&nbsp;exceeded <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">the street view of $0.89</a>.
Operating cash flow stood at $243.0 million. As of December 31, 2024, cash and cash equivalents came in at $1.45 billion.
The company disclosed a dividend per share of&nbsp;$0.38 effective first quarter of 2025, representing an annual increase of 5.6%.
Paul Brink, CEO said, &#8220;Post year-end, we also announced a financing package to support Discovery Silver&#8217;s acquisition of Newmont&#8217;s Porcupine Complex in&nbsp;Timmins. Together, the transactions have the potential to add 85-95K&nbsp;GEOs per annum to our medium-term production profile. These new additions, along with a number of new mine starts, contribute to the strong growth outlined in our 2025 guidance and outlook over the next five years.&#8221;
&#8221;We are encouraged that President Mulino has indicated a willingness to discuss Cobre Panama this year and that sentiment in&nbsp;Panama&nbsp;now appears more supportive of restarting the mine.&#8221;
Outlook: The company expects revenue for 2025 to be <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">higher by 25% Y/Y</a>.
Franco-Nevada expects a 14% Y/Y increase in Precious Metal GEOs and a 7% Y/Y increase in Total GEOs for 2025, excluding contributions from Cobre Panama.
For 2028, the company targets precious Metal GEOs to rise to between 400,000 and 440,000 GEOs, and Total GEOs to increase to between 505,000 and 565,000 GEOs, reflecting an 18% and 15% growth, respectively, compared to 2024.
For 2029, Precious Metal GEOs are projected to reach between 375,000 and 415,000 GEOs, and Total GEOs to grow to between 490,000 and 550,000 GEOs, representing an 11% and 12%, respectively, compared to 2024.
The five-year outlook anticipates the start of production at Valentine Gold, Stibnite, Eskay Creek, Castle Mountain Phase 2, the Coroccohuayco project at Antapaccay, the planned underground expansion at Candelaria, and the long-term expansion of Magino.
Investors can gain exposure to the stock via&nbsp;VanEck Gold Miners ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GDX#NYSE">GDX</a>).
Price Action: FNV shares are up 1.06% at $144.80 premarket at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44104459/toronto-risks-its-mining-hub-status-as-bureaucracy-and-geopolitics-take-toll" target="_blank" rel="noreferrer noopener">Toronto Risks Its Mining Hub Status As Bureaucracy And Geopolitics Take Toll</a></li>
</ul>
Photo via Shutterstock.

Large Cap

Guidance

Dividends

Franco-Nevada Reports Solid Q4 Earnings Amid Record Gold Prices, Eyes 25% Revenue Growth In 2025

Morgan Stanley analyst Keith Weiss initiates coverage on SailPoint (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIL#NASDAQ">SAIL</a>) with a Equal-Weight rating and announces Price Target of $26.

Morgan Stanley Initiates Coverage On SailPoint with Equal-Weight Rating, Announces Price Target of $26

Morgan Stanley analyst Michael Ulz initiates coverage on Aardvark Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AARD#NASDAQ">AARD</a>) with a Overweight rating and announces Price Target of $29.

Morgan Stanley Initiates Coverage On Aardvark Therapeutics with Overweight Rating, Announces Price Target of $29

Rosenblatt analyst Kevin Cassidy reinstates Super Micro Computer (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) with a Buy and announces $60 price target.

SMCI

Rosenblatt Reinstates Buy on Super Micro Computer, Announces $60 Price Target

SunCar Technology Group Inc. ("SunCar" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDA#NASDAQ">SDA</a>), an innovative leader in auto e-insurance and cloud-based B2B auto services in China, today announced it has secured a contract to develop and operate the insurance management platform for Leapmotor (09863.HK), one of China's fastest-growing electric vehicle manufacturers. The system will be integrated into Leapmotor's mobile app ecosystem, handling insurance issuance, claims processing, and accident services.
Leapmotor, founded in 2015, is a rising force in China's electric vehicle (EV) industry, specializing in intelligent and affordable EVs. According to CnEVPost, in 2024, the company delivered 293,724 vehicles, marking an over 104% year-over-year growth, with the monthly deliveries exceeding 40,000 units in the fourth quarter of 2024. According to Financial Times, Leapmotor has generated over 20 billion HKD in revenue in 2024.

Contracts

Market Index Target Term Securities Linked To The Dow Jones Industrial Average

SunCar Technology Awarded Contract To Develop Insurance Platform For Leapmotor's App Ecosystem

Press Releases

Cabaletta Bio to Participate in Guggenheim's Inaugural Healthcare Innovation Conference

Cabaletta Bio Reports Third Quarter 2024 Financial Results and Provides Business Update

Cabaletta Bio Presents Positive Clinical Safety and Efficacy Data on CABA-201 at ACR Convergence 2024

Cabaletta Bio to Participate in Upcoming Investor Conferences in December

General

Cabaletta Bio Outlines Strategic Priorities and Anticipated Key Milestones for 2025

Cabaletta Bio to Participate in Guggenheim's SMID Cap Biotech Conference

Cabaletta Bio Announces Presentations Featuring Updated Clinical Data on Rese-cel at Upcoming Scientific Meetings in February

Health Care

Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings

UPDATE - Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings

Comments

Cabaletta Bio

뉴스

파트너 / 기고자

벤징가 글로벌